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1. Introduction 
Today cancer is one of the leading diseases, which treat human life and enormous efforts are 
being done for its eradication. Currently many cancer types including breast cancer are 
treated by extensive surgery as well as chemo-radiotherapy. These treatment modalities 
usually present extensive damage to the patient both anatomically, physiologically and 
psychologically. In addition, chemo-radiotherapy shows extreme side effects of the other 
system in the body and their efficiencies are quite limited especially in disseminated 
metastatic cases. Recent developments and progress in human genome technology provided 
us to develop novel therapeutic methods. This progress also provided novel biomarkers, 
which early diagnose the cancer and predict the sensitivity of the current chemo-radiation 
therapies. 
Tight control by various regulatory mechanisms is applied on cell proliferation and growth 
in normal cells. However, certain genetic and epigenetic alterations permit the normal cells 
to avoid these mechanisms allowing indefinite cellular activities. Cancer is basically a 
genetic disease. The collection of genetic and epigenetic alterations of multiple genes and 
chromosomes lead to the development of cancer. In this regard, two major groups of tumor-
associated genes, oncogenes and tumor suppressor genes (TSGs), have been implicated in 
the carcinogenic process (Figure 1).  
TSGs have been defined as genetic elements whose loss or mutational inactivation allows 
cell to display one or more phenotypes of neoplastic growth [1]. TSG protein products are 
known to be involved in negative regulation of the cell cycle and proliferation and induction 
of apoptosis by different mechanisms. Thus inactivation of TSGs is one of the crucial steps 
during carcinogenetic process. In this process according to Knudson two-hit hypothesis for 
inactivation of TSGs [2], the deletion of targeted chromosomal regions (location of TSGs) 
eliminates one allele, while inactivating events (mutation, deletion, or epigenetic events such 
as promoter hypermethylation) affect the other allele of a concerning TSG [2]. The detection 
of frequent loss of heterozygosity (LOH) in a chromosomal locus is considered to be critical 
evidence for the localization of a TSG.  
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Fig. 1. Role of Oncogene and Tumor Suppressor Gene in Cancer. 
Two group of genes (oncogene and tumor suppressor gene) influence on physiological cell 
proliferation and growth. In cancer development, balance between these two groups of 
genes is broken. Either oncogene activation or tumor suppressor gene inactivation promotes 
cancer development.  
In fact many TSGs including well-known p53, RB1, p16, p21, and FHIT etc have been 
recently identified by using LOH analysis and then positional cloning. Inactivation of these 
classical TSGs usually occurs through deletion of one of its allele and mutation in the rest 
allele (Class I TSG, Knudson hypothesis). However, a novel class of TSGs with haploid 
insufficiency, in which one allele is lost and the remaining allele is haplo-insufficient, has 
been described recently, and the patients with these hemizygous TSGs in their genome are 
accepted as carriers for deficient allele of a TSG and they show a tumor-prone phenotype 
especially when challenged with carcinogens such as smoking, alcohol, x-ray, chemicals etc 
(Class II TSG) [3-7] (Figure 2). 
The novel TSG family, inhibitor of growth (ING), belongs to the group of genes that encodes 
proteins containing structural motifs involved in chromatin remodeling and transcription 
regulation. The ING family is classified as type II tumor suppressor since its inactivation has 
been implicated in neoplastic growth of various tumors [8-10]. Five human ING genes 
(ING1-5) have been identified and among them, ING1 is the founding member and the most 
widely studied. ING1 was first isolated using subtractive hybridization between short 
segments of cDNAs from normal and a number of breast cancer cell lines [11]. These 
randomly fragmented cDNAs interfered with the activity of tumor suppressors by either 
blocking protein production through anti-sense sequences or abrogating function in a 
dominant-negative fashion through truncated sense fragments [11]. Acute expression of 
transfected constructs encoding this gene inhibited cell growth while chronic expression of  
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Fig. 2. Cancer Development through Inactivation of Tumor Suppressor Genes. 
Knudson two-hit hypothesis for inactivation of TSGs, the deletion of targeted chromosomal 
regions (location of TSGs) eliminates one allele, while inactivating events (mutation, 
deletion, or epigenetic events such as promoter hypermethylation) affect the other allele of a 
concerning TSG (Class I). TSG with haploid insufficiency, in which one allele is lost and the 
remaining hemizygous allele is not enough to provide full suppression on cellular 
proliferation. These patients are carrier for deficient allele of a TSG and they show a tumor-
prone phenotype especially when challenged with carcinogens such as smoking, alcohol, x-
ray, chemicals etc (Class II). 
antisense ING1 constructs promoted transformation of mouse breast epithelial cells and 
increased the frequency of focus formation with NIH3T3 cells and protected cells from 
apoptosis [11, 12]. Using radiation hybrid analysis, ING1 gene was mapped on human 
chromosome 13q33-34 [13]. The other four members have been disclosed through sequence 
homologies with ING1, followed by functional in-vitro and then in-vivo cancer patient 
tissue analysis [9, 10, 14-16]. However, recent researches demonstrated opposite findings for 
some of ING family members such as ING2 as a possible oncogene in specific conditions. In 
fact, ING2 expression was found to be increased in colorectal cancer and knock-down of 
ING2 suppressed cell growth and induced cell cycle arrest or apoptosis [17]. 
2. Structure and function of ING family genes 
All members of ING family have distinct N-termini, which dictate the specific role of the 
ING members and, in certain instances, their antagonistic regulatory function [9,10,14-16]. 
Also all ING family members exhibit a highly conserved C-terminal plant homeodomain 
(PHD) that is commonly found in various chromatin remodeling proteins  [9,10,14-22] 
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(Figure 3). The PHD motif consists of about 60 amino acids and shows a C4HC3 ring 
structure that typically binds two Zn2+ ions [16]. Approximately 150 distinct PHD domain-
bearing proteins have been predicted to occur in humans [16]. PHD domains have been 
implicated in chromatin remodeling due to presence of their proteins as known components 
of larger chromatin remodeling complexes, and may function by strengthening a separate 
chromatin-binding activity of either the same protein or an associated protein [16]. 
Mutations within the PHD fingers of numerous proteins have been reported to be linked to 
tumorigenesis, immuno-deficiency syndromes, autoimmune syndromes, and several other 
genetic disorders [15, 23-26]. These mutations mainly occur at zinc-coordinating residues, 
suggesting that zinc ligation and hence integrity of the PHD finger fold are critical for the 
function of PHD finger-containing proteins [15]. 
 
 
Fig. 3. Structure and Interacting Domains of ING Family Proteins. 
All ING family proteins have a highly conserved plant homeodomain (PHD) finger motif, 
Novel Conserved Region (NCR) and Nuclear Localization Sequence (NLS). NLS directs ING 
to the nucleus through binding of the karyopherin/importins. NCR serves as an interacting 
site for lamin A as well as HAT/HDACs. The PHD finger binds to histone H3 and has a role 
in chromatin regulation. PCNA-interacting motif (PIP) and Partial Bromodomain (PBD) are 
specific to ING1. The PIP motif binds to PCNA and promotes ING1-mediated apoptosis. 
PBD domain binds SAP30 of mSin3A-HDAC1 and has a role in transcription regulation. All 
ING proteins except ING1 include LZL domain, which has roles in apoptosis and nucleotide 
excision repair of DNA. Both ING1 and ING2 include a short polybasic region called as PBR, 
to which PtdIns3P and PtdIns4P bind.  
All ING proteins contain nuclear conserved region (NCR) domain, which was identified by 
sequence analyses and is the second most highly conserved domain in the ING family proteins 
[15]. This N-terminal region of ING1 has been reported to interact directly with lamin A, 
suggesting that the association with nuclear lamina is a common feature of this family [27].  
All ING proteins contain a nuclear localization signal (NLS) at the carboxy terminal, and 
some of ING proteins have multiple NLS. Deletion of the NLS of ING1 resulted in 
cytoplasmic accumulation of the protein [28,29]. Translocation of ING proteins into the 
nucleus has been thought to be critical for their function because these molecules are nuclear 
proteins, and also it is clearly considered to be so by the observation of loss of nuclear ING1 
staining in a number of cancers [16, 30]. Deletion of the entire NLS of ING4 resulted in a 
protein that could no longer bind p53 in co-transfection experiments [31]. Moreover, two 
copies of a putative nucleolar translocation signal (NTS) were found within the NLS of 
ING1, and translocation of ING1 into the nucleolus following exposure to UV light was 
suggested to be required for ING1-associated apoptosis [16,28].  
All ING proteins, except ING1, contain leucine zipper-like (LZL) domain at the N-terminus. 
LZL domain forms a hydrophobic patch consisting of four to five conserved leucine or 
isoleucine residues spanning every seven amino acids. Similar leucine distribution has also 
been reported for ING3 to ING5 [15,32,33]. There is few information about the function of 
LZL and it been has reported that the LZL domain of ING2 is required for the induction of 
apoptosis and NER [34]. ING2 deletion mutants lacking the LZL domain do not show 
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increased apoptosis following UV exposure, suggesting that this domain is necessary for 
ING2-mediated apoptosis [34]. RNAi-mediated knockdown of ING2 has also been reported 
to abrogate the nucleotide excision repair (NER) capacity of melanoma cells [35].  
Within ING family members, only ING1 includes PCNA binding domain called as PIP box 
in a DNA damage-inducible manner at N-terminus. This domain indicates the role of ING1 
in DNA repair since PCNA has roles for DNA replication and repair. The interaction of this 
domain is specifically induced upon UV damage and has been thought to change PCNA 
activity away from DNA replication towards DNA repair [36]. Another unique domain 
present only in ING1b is called as PBD (partial bromodomain because of its sequence 
homology to bromodomains), which binds SAP30 of mSin3A-HDAC1, suggesting its role in 
transcriptional regulation of some genes [37]. 
Both ING1 and ING2 include a short polybasic region called as PBR at C-terminus. Though 
exact functions of this domain remain unknown, it has been reported that PtdIns3P and 
PtdIns4P can bind to the PBR [10,38], while PtdIns5P binds to the PHD motif of ING2 
[10,39].  
3. Genomic location, structure and expression of ING family genes 
Most ING family genes are ubiquitously expressed in human tissues. We characterized 
genomic structure of human ING1 gene, and demonstrated that the human ING1 gene 
contains three exons (1a, 1b and 2) and two introns [8]. The gene has been mapped to 
chromosome 13 (13q33-34), and it has been found to encode 4 different mRNA variants. 
ING1 is ubiquitously expressed in various tissues [8]. The second member of the ING 
family, ING2 gene, has been mapped on chromosome 4 (4q35.1) and has been known to 
have 2 variants; ING2a and ING2b [40]. ING2 has 3 exons including ex1a, ex1b and 2 [41]. 
Our group identified the ING3 gene on chromosome 7 (7q31). The ING3 also encodes 2 
different variants [9,10,41,42]. ING3 has 12 exons at its genomic location. The ING4 gene has 
been mapped on chromosome 12 (12q13.3) and encodes 8 variants with 8 exons [9,10,43,44]. 
The ING5 gene has been mapped on chromosome 2 (2q37.3) and encodes at least 5 different 
splicing variants with 8 exons [9,10,45].  
4. Biological functions of ING family genes 
ING proteins are involved in regulation of various cellular processes and signaling 
pathways such as angiogenesis, growth regulation, senescence, apoptosis, chemosensitivity, 
cell cycle, cell migration and DNA repair through p53-dependent and -independent 
pathways. ING proteins form complexes with HAT/HDAC [9,10,46]. After discovery of 
ING family genes prototype ING1, most of the functional studies have been conducted 
using ING1 variants, but fewer recently increasing studies, involving other ING family 
members, have also identified similar roles for these ING proteins. In addition, inhibition of 
ING proteins has been shown to increase cell spreading as well as migration, and relieve 
contact inhibition. 
p33ING1b physically associates with the p53 tumor suppressor protein and seems to be a 
critical cofactor in p53-mediated regulation of cell growth and apoptosis [9,10,46,47]. 
However in a separate study, p37Ing1, mouse variant of human p33ING1b, blocked cell 
proliferation regardless of p53 and did not affect p53-mediated cell growth arrest following 
DNA damage [48]. p37Ing1 in mice regulated Bax levels in a negative way and worked as a 
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prosurvival molecule following DNA damage independent of p53 status, complicating the 
function of ING1 in mouse and human and in various other circumstances. Moreover, recent 
experiments have also suggested that there are p53-independent functions for the ING 
proteins, including regulation of the NF-kB and hypoxia inducible factor (HIF) pathways 
[49-52].  
ING2 shows a high rate of homology with ING1 about 70% [9,10,30,34,53]. Similar to other 
members of the ING family, ING2 is reported to have function in cooperation with p53, 
which is important for modulation of p53-mediated chromatin remodeling [54]. p33ING2 
induces G1 phase cell cycle arrest or apoptosis in a p53-dependent manner following DNA 
damage [53]. ING2 has important roles in senescence, cellular response to DNA damage and 
DNA repair [34, 54]. Recently ING2 was also shown to interact with members of the 
transforming growth factor (TGF)-β signaling pathways enhancing transcription of target 
genes and cell cycle arrest [55]. However, overexpression of ING2 in colorectal cancer, 
burkitt lymphoma and cervical cancer and decreased expression in others such as head and 
neck carcinoma suggested that ING2 might have different function in various cancers 
[9,10,19,41,56,57]. Moreover, ING2 has 2 splicing variants and knockout experiments 
suggested oncogenic function of this gene [40,41]. In a recent study, a new function of ING2 
was identified for the control of DNA replication and the maintenance of genome stability 
[58]. 
We identified ING3 for the first time by a homology search in human genome and showed 
ING3 as a candidate tumor suppressor in head and neck cancer [42]. Overexpression of 
p47ING3 protein resulted in a decreased population of cells in S phase, a diminished colony-
forming efficiency, and induced apoptosis in RKO cells with wild type p53, but not in RKO-
E6 cells with inactivated p53, suggesting necessity of p53 protein for at least some of its 
functions [59]. Histone acetyl transferase (HAT) complexes are important regulators of gene 
expression and among these, the NuA4 complex, first characterized in yeast, stands out as it 
controls multiple key nuclear functions in eukaryotic cells such as regulation of 
transcription, cell-cycle progression as well as the process of DNA repair [60]. p47ING3 
activates p53-transactivated promoters, including promoters of p21/waf1 [61] and ING3 has 
been a stable component of Tip60/NuA4 HAT complex that cooperates with p53 and 
blocked cell cycle by activating the p21/waf1 gene [9,10,62,63]. Tip60 is an important 
transcriptional cofactor for p53-, NF-kB- and Myc-dependent transcription activation, 
suggesting that ING3 might have functions for many processes such as apoptosis and 
metastasis suppression at the transcription level through its association with the 
Tip60/NuA4 complex [63]. ING3 expression significantly promoted apoptosis by activating 
the Fas/caspase-8 pathway, suggesting that ING3 may also be involved in the death-
receptor pathways [9,10,15,64]. Recently ING3 has been reported to be degraded by the 
ubiquitin-proteasome pathway through the SCF (Skp2) complex and interruption of ING3 
degradation enhanced the tumor-suppressive function of ING3 [65]. 
p29ING4 was identified by Shiseki et al [66]. Overexpression of ING4 protein resulted in a 
diminished colony-forming efficiency, a decreased cell population in S phase, and the 
induction of apoptosis in a p53-dependent manner. p29ING4 also activated the p21/waf1 
promoter, and induce p21/WAF1 expression [66].  
ING4 has been proposed to regulate cell cycling and apoptosis. ING4 has been reported to 
inhibit angiogenesis by various studies besides its role for cellular processes common for all 
ING family members [67-69]. It has been demonstrated that ING4 physically interacts with 
p65 (RelA), a subunit of nuclear factor NF-kB, and that ING4 regulates angiogenesis through 
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transcriptional repression of NF-kB-responsive genes in brain tumors [70]. ING4 functional 
studies suggest that this gene in addition to the common functions of the ING proteins 
could play a completely different role in tumorigenesis. Actually, ING4 is likely to be 
involved in inhibition of the cell's spreading and migration as well as tumor angiogenesis. 
Indeed, its loss results in loss of contact inhibition, activation of NF-kB transcriptional 
activity and enhanced cell migration. Thus ING4 deficiency may be a crucial step in 
malignant progression, especially for glioblastoma [9,10,15,16,66,71-75].  
ING4 also associates with HBO1 (HAT binding to ORC1)/HAT complex [63,76]. It was 
shown that interaction between ING4 and H3K4me3 augments HBO1 acetylation activity on 
H3 tails and drives H3 acetylation at ING4 target promoters, which facilitates apoptosis in 
response to genotoxic stress and inhibits anchorage-independent cell growth, and these 
functions depend on ING4 interaction with H3K4me3 [77]. ING4 was recently reported to 
interact with tumor suppressor p53 through interaction with NLS domain and negatively 
regulate the cell growth with significant G2/M arrest of cell cycle in HepG2 cells through 
up-regulation of p53-inducible gene p21 [31,78]. 
Similar to ING4, ING5 was also identified by Shiseki et al [66]. Overexpression of ING5 
protein also resulted in a diminished colony-forming efficiency, a decreased cell population 
in S phase, and the induction of apoptosis in a p53-dependent manner. p28ING5 protein 
activated the p21/waf1 promoter, and induced p21/WAF1 expression [66]. Relatively little 
information is available in the literature for ING5. Doyon et al. recently identified MOZ 
(monocytic leukemia zinc finger protein)/MORF (MOZ related factor) and HBO1 to be 
catalytic native subunits of ING5 complexes, which are necessary for their activity [63]. The 
MOZ, and the related factor MORF also form tetrameric complexes with Esa1-associated 
factor 6 ortholog (EAF6), and the bromodomain- and PHD finger protein (BRPF)-1, -2, or -3. 
BRPF proteins are rich in domains found in chromatin-associated factors, like PHD fingers 
and bromodomain. Ullah and his group found that BRPF proteins bridge the association of 
MOZ and MORF with ING5 and a homolog of yeast Esa-1 associated factor 6 (EAF6) 
[9,10,79]. ING5 as an adapter molecule links the MOZ/MORF and HBO1/HAT complexes. 
PHD fingers of ING proteins recognize histone H3 methylated at lysine 4 at the chromatin, 
suggesting the functional role of ING5 in the chromatin remodeling process [79, 80].  
5. Disorders of ING family genes in human tumors 
Rearrangement of ING1 gene locus was demonstrated in one neuroblastoma cell line and 
reduced expression in primary cancers and cell lines in early clinical studies at the time of 
ING1 cloning [8-11]. Following ING1 cDNA cloning, we identified the genomic structure of 
the human ING1 gene and showed its tumor suppressor character for the first time by 
finding its chromosomal deletion at the 13q34 locus and tumor-specific mutations in a 
number of head and neck squamous cell carcinoma (HNSCC) samples [8].  
Few studies have analyzed the mRNA expression status of ING family genes in various 
human cancers. Toyama et al. found decrease of ING1 mRNA expression in about half of 
breast cancer samples and all of the breast cancer cell lines they examined [47]. Another 
study also revealed reduced expression of breast cancer samples [81]. Down-regulation of 
ING1 mRNA has also been demonstrated in various other cancer types, including lymphoid 
malignancies, gastric tumors, brain tumors, lung cancer, ovarian cancer and esophagogastric 
carcinomas, though no comprehensive clinical correlation was performed [9,10,15,16,82-90]. 
Uncommon missense mutations and reduced protein expression of ING1 have also been 
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detected in esophageal carcinomas [91], and colon cancer cell lines [83] while no mutation 
was detected in leukemia [84,92], oral cancers [93] and lymphoid malignancies [82].  
For loss of ING gene and their protein functions, loss of heterozygosity (LOH), promoter 
CpG hypermetylation and nucleo-cytoplasmic protein mislocalization have been proposed 
[9,10,15,16]. Using methylation-specific PCR, the p33ING1b promoter was methylated and 
silenced in almost a quarter of all cases in primary ovarian tumors [89]. No differences or 
increased expression of ING1 were observed in recent studies of myeloid leukemia or 
melanoma [92,94].  
Recently reduced expression of ING2 mRNA as well as protein was observed in 
hepatocellular carcinoma (HCC) [95]. Decreased ING2 expression (but not ING2 mutation) 
has been observed in lung cancer [96]. Decrease of nuclear ING2 protein was observed in 
melanoma [57]. On the other hand increased expression of ING2 mRNA was shown in colon 
cancer [97]. We recently demonstrated that frequent deletion of ING2 locus at 4q35.1 
associated with advanced tumor stage in HNSCC [98]. Moreover, ING2 may play a role in 
melanoma initiation, since reduction of nuclear ING2 has been reported in radial as well as 
vertical growth phases, and metastatic melanoma as compared to dysplastic nevi [57]. On 
the other hand, reduced ING2 expression was associated with tumor progression and 
shortened survival time in HCC [95]. These epidemiological studies suggest that ING2 loss 
or reduction may be important for tumor initiation and/or progression [9,10,15,16].  
We showed frequent allelic loss of ING3 in HNSCC [42]. But ING3 mutation was very rare in 
our study (a sole missense mutation of ING3 at codon 20). In another recent study using a 
large study population, we revealed that down-regulation of ING3 was more evident in late-
stage tumors as compared with early stage patients, and patients with low ING3 mRNA 
expression demonstrated worse survival rates as compared to the patients with normal-high 
ING3 expression [99]. As shown for ING2, decreased nuclear ING3 protein expression was 
associated with a poor survival rate. The survival rate was 93% for the patients with strong 
nuclear ING3 staining, whereas it declined to 44% for the patients with negative-to-moderate 
nuclear staining [100]. In a recent study, we also demonstrated frequent deletion of 
chromosomal locus of each of ING family member including ING3 in ameloblastomas [101].  
ING4 mRNA was decreased in glioblastoma and associated with tumor progression [70]. 
Decreased ING4 has been associated with increased expression of IL-8 and osteopontin 
(OPN) in myeloma [9,102]. In both reports, decreased ING4 expression was associated with 
higher tumor grade and increased tumor angiogenesis. In myeloma, it was also associated 
with increased expression of interleukin-8 and osteopontin [9,102]. Expression of ING4 was 
decreased in malignant melanoma as compared to dysplastic nevi, and was found to be an 
independent poor prognostic factor for the patients [73]. ING4 was found to suppress the 
loss of contact inhibition and growth. Moreover some mutation and deletion were detected 
in cell lines derived from human cancers such as breast and lung [103]. 
We reported reduced expression level of ING4 and frequent LOH of the ING4 locus in 
HNSCC [43]. No mutation of the ING4 gene was found in head and neck cancers. 
Significant reduced expression of ING4 was detected in gliomas as compared with normal 
human brain tissue, and the extent of reduction correlated with the progression from lower 
to higher grades of tumours [70]. Klironomos et al. investigated immunohistochemically the 
expression pattern of ING-4, NF-kappaB and the NF-kappaB downstream targets MMP-2, 
MMP-9 and u-PA in human astrocytomas from 101 patients. They found that ING-4 
expression was significantly reduced in astrocytomas, and it was associated with tumor 
grade progression. Expression of a NF-kappaB subunit p65 was significantly higher in grade 
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IV than in grade III and grade I/II tumors, and a statistical significant negative correlation 
between expression of ING-4 and expression of nuclear p65 was noticed [104].  
Recently Nagahama et al. reported up-regulation of ING4 in a human gastric carcinoma cell 
line (MKN-1) by promoting mitochondria-mediated apoptosis via the activation of p53 
[105]. Both mRNA and protein of ING4 expression were down regulated in hepatocellular 
carcinoma tissues. ING4 expression level correlated with prognosis and metastatic potential 
of hepatocellular carcinoma [106]. In another recent study, ING4 mRNA and protein 
expression were examined in gastric adenocarcinoma tissues and human gastric 
adenocarcinoma cell lines by RT-PCR, real-time RT-PCR, tissue microarray 
immunohistochemistry, and western blot analysis [107]. Their data showed that ING4 
mRNA and protein were dramatically reduced in stomach adenocarcinoma cell lines and 
tissues, and significantly less in female than in male patients. Decrease of ING4 mRNA 
expression was found to correlate with the stage of the tumour [107]. Wang et al. examined 
ING4 protein expression in 246 lung cancer samples and overall reduced ING4 expression 
and higher ING4 expression in cytoplasm than in nucleus of tumour cells were detected, 
suggesting its involvement in the initiation and progression of lung cancers [108].  
In a recent study, nuclear expression of ING4 was found to gradually decrease from non-
cancerous epithelium and dysplasia to HNSCC and was negatively correlated with a 
poorly-differentiated status, T staging, and TNM staging in HNSCC. On the other hand, 
cytoplasmic expression of ING4 was significantly enhanced in HNSCC and was 
significantly associated with lymph node metastasis and 14-3-3η expression. Moreover, 
nuclear expression of ING4 was positively correlated with p21 and p300 expression and 
with the apoptotic index. Their results suggested that the decreases in nuclear ING4 and 
cytoplasmic translocation of ING4 protein play important roles in tumorigenesis, 
progression and tumor differentiation in HNSCC [109].  
Examination of ING4 protein expression levels in colorectal cancer samples from 97 patients 
showed that ING4 protein was down regulated in adenoma relative to normal mucosa and 
further reduced in colorectal cancer tissues. Decrease of ING4 protein expression was also 
related to the more advanced Dukes' stages and ING4 expression levels in patients with 
lymphatic metastasis were lower than those without metastasis, suggesting that ING4 play a 
role in colorectal carcinoma progression [110].   
Our group reported the first study linking ING5 chromosome locus to a human cancer. We 
demonstrated a high ratio of LOH in oral cancer using 16 microsatellite markers on the long 
arm of chromosome 2q21-37.3 [111]. ING5 appeared to be a strong candidate tumor 
suppressor in this study though several other candidate TSGs including ILKAP, HDAC4, 
PPP1R7, DTYMK, STK25, BOK are also localized at the area, where frequent deletion has 
been detected [9,10,111]. Moreover, our recent study revealed decreased expression of ING5 
mRNA and mutations in oral cancer samples as compared to their corresponding normal 
controls, suggesting its tumor suppressive role in cancer [45]. Examination of 172 cases of 
HNSCC for ING5 protein by immunohistochemistry using tissue microarray, and in 3 oral 
SCC cell lines by immunohistochemistry and Western blot showed that a decrease in 
nuclear ING5 localization and cytoplasmic translocation were detected, supporting the 
previous studies and strong involvement of ING5 in tumorigenesis and tumor 
differentiation in HNSCC [112]. 
Xing et al. analyzed ING5 expression in gastric carcinoma tissues and cell lines (MKN28, 
MKN45, AGS, GT-3 TKB, and KATO-III) by Western blot and reverse transcriptase-
polymerase chain reaction. An increased expression of ING5 messenger RNA was found in 
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gastric carcinoma in comparison with paired mucosa and lower expression of nuclear ING5 
protein and cytoplasmic translocation was detected in gastric dysplasia and carcinoma than 
that in nonneoplastic mucosa [113]. Nuclear ING5 expression was negatively correlated 
with tumor size, depth of invasion, lymph node metastasis, and clinicopathologic staging, 
whereas cytoplasmic ING5 was positively associated with depth of invasion, venous 
invasion, lymph node metastasis, and clinicopathologic staging [113]. 
6. Abnormalities of ING family genes in breast cancer 
Abnormalities of ING family members are linked to etiopathogenesis of various cancers 
including breast cancer. In fact, ING1, the founding member, was first isolated using a 
method that combined PCR-mediated subtractive hybridization of cDNAs from normal and 
breast cancerous cells [11]. Later same group examined ING1 mutation and mRNA 
expression in breast cancer cell lines and in a large number of primary breast cancers [47]. 
Within 377 breast cancer patients analyzed for mutation of ING1, one germ-line missense 
and three germ-line silent alterations were detected. Then mRNA analysis was randomly 
examined in 48 breast cancer samples. Their results showed that ING1 mRNA expression 
was decreased (2-10-fold) in 44% (21 out of 48 cases) of breast cancer tissues compared to 
adjacent normal tissues, while 33% (16/48) of the tumors demonstrated levels similar to 
control sample and 23% (11/48) showed increases in ING1 mRNA. All of the 10 breast 
cancer lines displayed decreased ING1 mRNA expression. Using in situ hybridization, 
decrease of mRNA in breast cancer cells was also confirmed as compared to adjacent normal 
cells. Using a monoclonal antibody against ING1, similar levels of the protein was also 
demonstrated in randomly selected 10 breast cancer samples [47]. When the relationship 
between ING1 mRNA expression levels and clinicopathological factors of breast cancer 
samples was examined, probability of metastasis to regional lymph nodes was significantly 
increased in ING1-decreased samples. Only one of 11 tumors (%9) with increased ING1 
mRNA expression metastasized to lymph nodes, whereas 11 of 19 cases (58%) with 
decreased expression of ING1 showed metastasis to lymph nodes [47].  
Tokunaga et al. examined the expression of ING1 mRNA in breast cancer cell lines and 
clinical breast cancer tissues, using quantitative RT-PCR and real-time TaqManTM 
technology [81]. Decreased expression of ING1 mRNA was found in 71% of the breast 
cancer samples as compared to adjacent normal tissues. The authors has also examined p53 
mutation status by immunohistochemistry and decreased ING1 expression was detected in 
9 of 15 tumors that were negative for p53 immunostaining (i.e, wild type). Decrease of ING1 
mRNA was speculated to be responsible for malfunction of p53 in these cases [9,10,81].     
In an immunohistochemical study performed by Nouman et al, 69 (80%) out of 86 breast 
cancer cases showed reduced expression of p33ING1b protein. On the other hand, strong 
nuclear expression of ING1 protein was detected in normal breast lobules and adjacent 
stroma. Correlation of each of estrogen and progesterone receptor status demonstrated a 
positive response with nuclear expression of p33ING1b protein. Nuclear loss of ING1 
protein was associated with a concomitant enhancement of cytoplasmic p33ING1b 
expression in a proportion of the cases, suggesting as a cause for loss of normal function of 
the ING1 protein [114]. Similar reduced nuclear expression of p33ING1b protein was also 
shown in acute lymphoblastic leukemia [115], melanoma [116]. 
Toyama et al. reported that p33ING1b increased ERα transcriptional activity stimulated by 
estrogen through AF2 domain [10, 117]. In another research, p40, a protein highly 
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homologous to breast carcinoma metastasis suppressor 1 (BRMS1), was found to be unit of 
the mammalian Sin3A co-repressor complex including RBP1 and p33ING1b and 
overexpression of p40 in human cells inhibited cell growth by recruiting the HDAC1 
deacetylase complex. When tethered to the promoter by Gal-DNA binding domain, p40 can 
repress transcription of the luciferase reporter gene [118].  
Kim et al. tried to identify genes that can suppress oncogenic properties such as loss of 
contact inhibition elicited by overexpression of MYCN. Their screen data revealed ING4 as a 
suppressor of loss of contact inhibition. Then they hypothesized that a deficiency of ING4 
may play a role in tumorigenesis. For this aim, they examined ING4 transcripts in human 
cancer cell lines. They found a common deletion in various cancer cell lines including a 
breast cancer cell, T47D. Deletion of the four highly charged amino acid residues (KGKK) 
would result in mislocalization of the ING4 protein, thereby impairing its function [103]. 
Later this deletion was reported to be a source of alternative splicing variants of ING4 and 
was linked to abnormalities of subcellular localization of ING4 [71]. Besides Kim et al. also 
performed southern blot analysis for ING4 locus deletion in 55 breast cancer cell lines using 
2 BAC probe within ING4 locus at 12p13.31. These probes, BAC RP11-272L6 and BAC RP11-
59H1, were shown to be deleted in 24% and 11% of the cells including T47D breast cancer 
cell line, respectively [103].  
In a recent study, ING4 was found to suppress an initial hyperplastic response to the 
oncogene MYC in a mouse model of breast cancer. In addition, they showed that a C-
terminal truncation mutant of ING4 found in a human neuroblastoma cell line induced 
mammary hyperplasia and exacerbated MYC-initiated mammary tumorigenesis, suggesting 
that ING4 can function as a tumor suppressor gene in breast tissue [119].  
In another recent report, therapeutic effect of adenovirus-mediated ING4 (Ad-ING4) gene 
therapy was investigated in human breast cancers in vitro and in vivo in an athymic nude 
mouse model, using two human breast carcinoma cell lines MDA-MB-231 (mutant p53) and 
MCF-7 (wild-type p53). The results displayed that Ad-ING4 treatment could induce in vitro 
significant growth suppression in both mutant p53 MDA-MB-231 and wild-type p53 MCF-7 
breast carcinoma cells despite p53 status. Moreover the study further revealed that Ad-ING4 
gene transfer resulted in G2/M phase arrest and apoptosis, upregulation of p21, p27, and 
Bax, downregulation of Bcl-2, IL-8, and Ang-1, promoted cytochrome c release from 
mitochondria into cytosol, and activated caspase-9, caspase-3, and PARP in mutant p53 
MDA-MB-231 breast carcinoma cells. Furthermore, intratumoral injections of Ad-ING4 in 
nude mice bearing mutant p53 MDA-MB-231 breast tumors clearly inhibited the human 
breast xenografted tumor growth and decreased CD34 expression of tumor vessels and 
microvessel density. All these results suggest that Ad-ING4 is a potential candidate for 
breast cancer gene therapy [120]. 
ING4 was detected to be deleted in 170 (16.5%) of 1033 breast cancer samples using two 
color FISH with a probe of BAC RP11-433J6 including ING4 locus. Comparison of 
clinicopathological variables with ING4 deletion status in these breast cancer samples 
showed significant difference for Her2 expression status. Thirty- nine (23.8%) of 164 of 
tumors with ING4 deletion were HER2 positive, as compared with 115 (14.1%) of 814 of 
tumors without deletion. In another way, 25.3% (39/ 154) of HER2-positive tumors 
harbored ING4 deletion as compared to 15.1% (125/824) of HER2-negative tumors, 
indicating that ING4 deletion is more common in HER2- positive tumors [121]. In breast 
cancer, there is no report yet regarding with other members of ING family, ING2, 3 and 5. A 
summary of alterations of ING family genes in breast cancer is shown in table 1.   
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ING Gene Alteration Reference 
ING1 Mutation,    mRNA expression,    protein expression 47 
ING1 mRNA expression 81 
ING1 Nuclear protein,    Cytoplasmic protein 114 
ING1 Induction of ERα activity 117 
ING4 Deletion at chromosomal locus 103 
ING4 Suppression of MYC-induced carcinogenesis 119 
ING4 
Ad-ING4-treated suppression of cancer cells and tumor 
growth 
120 
ING4 Deletion at chromosomal locus 121 
Table 1. Alterations of ING Family Genes in Breast Cancer. 
7. Future prospects  
Nearly 15 years of research after discovery of the first member of ING family gene, ING1, 
there are more accumulating data which show importance of these gene family in multiple 
cellular functions such as transcription, chromatin regulation, cell cycling, angiogenesis, cell 
transformation, apoptosis, growth regulation, senescence, DNA repair and tumorigenesis 
etc. Recent knowledge on this family displays that the family members have common and 
separate functions in human cancer. Though at the beginning, all members were considered 
to be tumor suppressor, recent evidences show a complex situation with oncogenic 
functions for at least some of the members and in some specific conditions. Thus both 
diagnostic and therapeutic approach should be revisited according to their functional roles 
in various conditions and tumor types. Though much work is necessary for clarifying the 
exact functions of these genes to provide therapy for various human cancers, promising 
results are noticed at the moment for usability of these genes as a therapeutic and diagnostic 
target. Thus progress on the knowledge of functions of ING family genes as well as the 
relationship with p53 and other unknown molecules will clarify their roles in cancer, which 
will result in their uses in cancer diagnostics as well as therapy soon. 
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